Marinomed Biotech AG's latest marketcap:
As of 09/26/2025, Marinomed Biotech AG's market capitalization has reached $42.55 M. According to our data, Marinomed Biotech AG is the 31814th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 42.55 M |
| Revenue (ttm) | 11.4 M |
| Net Income (ttm) | 10.65 M |
| Shares Out | 1.84 M |
| EPS (ttm) | 5.99 |
| Forward PE | 1.58 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/17/2025 |
Marinomed Biotech AG's yearly market capitalization.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 09/26/2025 | €36.43 M | $42.55 M | 37.61% | 31814 |
| 12/30/2024 | €26.67 M | $27.61 M | -39.87% | 32033 |
| 12/29/2023 | €44.36 M | $48.96 M | -47.78% | 27895 |
| 12/30/2022 | €84.95 M | $90.92 M | -34.78% | 22884 |
| 12/30/2021 | €130.25 M | $148.05 M | -25.67% | 20613 |
| 12/30/2020 | €175.25 M | $214.04 M | 19.23% | 16399 |
| 12/30/2019 | €146.98 M | $164.8 M | 15640 |
Company Profile
About Marinomed Biotech AG
Marinomed Biotech AG is a biopharmaceutical company specializing in therapeutic products for virology and immunology. Headquartered in Korneuburg, Austria, the company operates across Europe and internationally.
Business Segments
The company operates through three key segments:
- Virology – Focuses on treatments for viral respiratory infections.
- Immunology – Develops therapies for immune-related conditions.
- Other – Includes additional research and development initiatives.
Product Pipeline
Marinomed Biotech AG has a diverse portfolio of products, including:
- Budesolv – A treatment for allergic rhinitis.
- Tacrosolv – Currently in Phase II clinical trials for inflammatory eye diseases.
- Carravin – Designed to alleviate nasal congestion.
- Inhaleen – Targets viral pneumonia.
- Carragelose – Includes nasal/throat sprays and lozenges for respiratory infections.
Partnerships & History
The company has a technology partnership with SPH Sine Pharmaceutical Laboratories Co. Ltd. Originally founded in 2006 as Marinomed Biotechnologie GmbH, it rebranded to Marinomed Biotech AG in June 2017.
Frequently Asked Questions
-
What is Marinomed Biotech AG's (VIE-MARI) current market cap?As of 09/26/2025, Marinomed Biotech AG (including the parent company, if applicable) has an estimated market capitalization of $42.55 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Marinomed Biotech AG (VIE-MARI) rank globally by market cap?Marinomed Biotech AG global market capitalization ranking is approximately 31814 as of 09/26/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.